Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs EHang Holdings Ltd - ADR (EH) Price & Performance

Amphastar Pharmaceuticals IncTrade
EHang Holdings Ltd - ADRTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs EHang Holdings Ltd - ADR — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while EHang Holdings Ltd - ADR trades at $5.79 (market cap $435.35M). The key difference: Amphastar Pharmaceuticals Inc is the larger of the two by market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals.

AMPHEH
Market Cap
$863.95M$435.35M
Sector
HealthIndustrials
52-Week High
$30.81$19.44
52-Week Low
$16.87$4.90
Enterprise Value
$1.26B$374.58M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

EHang Holdings Ltd - ADR

EHang Holdings (EH) trades at $5.74, up 7.69% in the last session, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported Q1 2026 revenue of $418 million, flat year-over-year, but with a significant net loss of $276 million, reflecting ongoing profitability challenges despite a high gross margin of 61.53%. Recent news highlights operational progress, including the first pilotless eVTOL flight in Central Asia, but the stock remains volatile amid sector-wide pressures.

The outlook for EH is highly speculative, with substantial execution risks and negative earnings overshadowing long-term potential in the advanced air mobility market. Analyst sentiment is divided, with a consensus price target of $6.97 offering limited upside, while institutional ownership trends and cash flow volatility underscore the high-risk nature of the investment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About EHang Holdings Ltd - ADR

EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.

Read more on EH